Spark Therapeutics (ONCE) : The total negative money flow of $2.19 million on Tuesday indicates selling on strength. The inflow of money on upticks was $4.3 million, compared to $6.49 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.66. The negative money flow of $0 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $0.1 million. The price action in the Spark Therapeutics (ONCE) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $56.53 with a gain of $1.78 , a change of 3.25% over the previous days close. The stock registered 3.21% for the week.
Also, RBC Capital initiates coverage on Spark Therapeutics (NASDAQ:ONCE) . Analysts at the RBC Capital have a current rating of Outperform on the shares. The rating by the firm was issued on July 12, 2016.
Spark Therapeutics, Inc. has lost 3.05% in the last five trading days and dropped 4.32% in the last 4 weeks. Spark Therapeutics, Inc. is up 0.18% in the last 3-month period. Year-to-Date the stock performance stands at 24.3%.
Spark Therapeutics (NASDAQ:ONCE): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $54.62 and $54.60 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $57.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $56.32, notching a gain of 2.87% for the day. The total traded volume was 361,405 . The stock had closed at $54.75 on the previous day.
In a related news,The director 10% owner of Spark Therapeutics, Inc., ChildrenS Hospital Of Philade sold 1,000,000 shares at $60.9 on August 16, 2016. The Insider selling transaction had a total value worth of $60,900,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.